Toll-like receptor-4 and lipoprotein accumulation in macrophages.
Excessive lipid accumulation in macrophages, also known as foam cell formation, is a key process during the development of atherosclerosis, leading to vascular inflammation and plaque growth. Recent studies have identified a new mechanism of macrophage lipid accumulation in which minimally oxidized low-density lipoprotein (mmLDL) and its active components, polyoxygenated cholesteryl ester hydroperoxides, are involved in endogenous activation of toll-like receptor-4 (TLR4), leading to recruitment of spleen tyrosine kinase (Syk), robust cytoskeletal rearrangements and macropinocytosis. In hyperlipidemic environments, mmLDL-induced, TLR4- and Syk-dependent macropinocytosis leads to substantial lipid accumulation in macrophages and monocytes, which may constitute an important mechanism of foam cell formation in atherosclerosis. A novel hypercholesterolemic zebrafish model of early stages of atherosclerosis was used to demonstrate that the TLR4 deficiency significantly reduces the in vivo rate of macrophage lipid accumulation in vascular lesions.
Miller
Yury I
YI
Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA. yumiller@ucsd.edu <yumiller@ucsd.edu>
Choi
Soo-Ho
SH
Fang
Longhou
L
Harkewicz
Richard
R
D000818:Animals; D050197:Atherosclerosis / Q000473:pathology; D002788:Cholesterol Esters / Q000378:metabolism; D005487:Foam Cells / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism* / Q000502:physiology; D008264:Macrophages / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D008954:Models, Biological; D051197:Toll-Like Receptor 4 / Q000378:metabolism*; D015027:Zebrafish
D002788:Cholesterol Esters; D008077:Lipoproteins, LDL; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4
Trends Cardiovasc Med. 2004 Jul;14(5):191-5
15261891
Atherosclerosis. 2003 Sep;170(1):187-90
12957699
Circ Res. 2009 Apr 24;104(8):952-60
19265037
J Exp Med. 2008 Feb 18;205(2):373-83
18250194
Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):e61-4
14563652
N Engl J Med. 2002 Jul 18;347(3):185-92
12124407
Biochem Biophys Res Commun. 2005 Dec 9;338(1):128-35
16105647
J Clin Invest. 2005 Aug;115(8):2072-5
16075051
J Biol Chem. 2003 Jan 17;278(3):1561-8
12424240
Circulation. 2005 May 24;111(20):2654-61
15883205
Clin Exp Immunol. 2006 Feb;143(2):269-73
16412050
Curr Drug Targets. 2007 Dec;8(12):1249-63
18220702
FASEB J. 2008 Oct;22(10):3595-606
18559988
J Neurol. 2004 Jul;251(7):853-8
15258789
J Biol Chem. 2006 Jun 9;281(23):15757-62
16606620
Mol Aspects Med. 2003 Aug-Oct;24(4-5):239-50
12893002
J Biol Chem. 2008 Apr 18;283(16):10241-51
18263582
J Lipid Res. 2009 Apr;50 Suppl:S388-93
19106070
J Biol Chem. 2005 Jan 21;280(3):2352-60
15533943
Biochim Biophys Acta. 1992 Oct 30;1128(2-3):117-31
1420284
BMC Med Genomics. 2008 Nov 28;1:60
19040724
Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2384-91
17872459
Circulation. 2007 Oct 16;116(16):1832-44
17938300
Circ Res. 2009 Jun 19;104(12):1355-63
19461045
Nat Med. 2004 Apr;10(4):416-21
15034566
Pharmacogenet Genomics. 2005 Jan;15(1):15-21
15864121
Arteriosclerosis. 1984 Jul-Aug;4(4):323-40
6466191
Circulation. 2004 Oct 5;110(14):2024-31
15451785
Eur J Clin Invest. 2004 Feb;34(2):94-9
14764071
J Lipid Res. 1995 Sep;36(9):1996-2004
8558087
Circ Res. 2009 Jan 30;104(2):210-8, 21p following 218
19096031
Mol Biol Cell. 2003 Oct;14(10):4196-206
14517329
Am J Pathol. 2002 Feb;160(2):701-10
11839591
Curr Opin Lipidol. 2003 Oct;14(5):437-45
14501582
Circulation. 2001 Dec 18;104(25):3103-8
11748108
Circulation. 2003 May 20;107(19):2416-21
12742999
J Biol Chem. 2009 Jul 31;284(31):21077-89
19509298
Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1213-9
15718493
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10679-84
15249654